Disease · MONDO_0004849
Trials27
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 27
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02850978 | Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease | 1,335 | 2019-12-06 | Pulmonary Disease, Chronic Obstructive | TIOTROPIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT00261833 | Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency | Phase 4 | 180 | 2015-01-19 | Alpha1-proteinase Inhibitor Deficiency, Emphysema | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT00670007 | Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency. | Phase 4 | 140 | 2016-07-12 | Emphysema, Alpha 1-proteinase Inhibitor Deficiency | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT02006576 | Prostaglandin Inhibition for Emphysema | Phase 2 | 118 | 2019-12-16 | Emphysema | IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00874497 | Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema | Phase 2 | 84 | 2017-04-17 | Chronic Obstructive Pulmonary Disease | TETOMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT00263887 | Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE) | Phase 2 | 77 | 2014-08-21 | Alpha 1-Antitrypsin Deficiency | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT01014442 | A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients | Phase 3 | 68 | 2017-02-10 | Lung Transplantation | MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT03679598 | Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency | Phase 2 | 63 | 2024-07-09 | Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD | ALVELESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01744093 | Doxycycline for COPD in HIV-Infected Patients | Not applicable | 61 | 2018-10-10 | HIV, Chronic Obstructive Pulmonary Disease (COPD), Emphysema | DOXYCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT02525861 | GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study | Phase 3 | 34 | 2021-10-14 | Alpha1-antitrypsin Deficiency | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT03244059 | Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies | Phase 2 | 17 | 2023-07-18 | Chronic Obstructive Pulmonary Disease, Emphysema | BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03008915 | Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency | Phase 2 | 15 | 2021-02-17 | Alpha-1 Antitrypsin Deficiency, Emphysema, Chronic Obstructive Pulmonary Disease | ASPIRIN | Its record names the disease | ClinicalTrials.gov |
| NCT01110252 | Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease | Not applicable | 4 | 2012-03-26 | Chronic Obstructive Pulmonary Disease, Pulmonary Emphysema | FILGRASTIM | Its record names the disease | ClinicalTrials.gov |
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) | Phase 3 | 345 | Pulmonary Emphysema in Alpha-1 PI Deficiency | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency | Phase 3 | 290 | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00232674 | Efficacy Study of the Effect of Budesonide on Emphysema | Phase 4 | 240 | Chronic Obstructive Pulmonary Disease | BUDESONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00056264 | A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD | Phase 3 | 234 | Chronic Obstructive Pulmonary Disease, COPD | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01217671 | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema | Phase 2/3 | 168 | Emphysema | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00269126 | Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) | Phase 3 | 150 | Pulmonary Disease, Chronic Obstructive | FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05382208 | Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial) | Phase 2 | 133 | Emphysema, HIV | DOXYCYCLINE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004849/trials